Glaxo va al cine ALLI...

Glaxo, the pharmaceutical giant behind Alli, an over-the-counter weight-loss product, has decided that a good way to educate Americans about obesity — and increase sales of Alli — is to finance a “hard-hitting” documentary about eating.

Although a budget has not been set, an Academy Award-winning director will be named on Jan. 25 at the Sundance Film Festival, a spokesman for Glaxo said.

To lend credibility to the project, Glaxo sought out a partner: the Creative Coalition, a nonprofit social and political advocacy organization backed by prominent entertainers like Alec Baldwin, Tim Daly and Susan Sarandon. The organization has decided to produce the film with Glaxo, aiming to deliver a finished picture this year. Although theatrical distribution is a goal, distribution plans are incomplete.

“This won’t be a marketing tool at all,” said Robin Bronk, the Creative Coalition’s executive director, adding that working with Glaxo on the project is “a natural progression of our mission to develop educational projects.”

Ver más...

La OTC_ión de GLAXO...

En abril 2011 dieron ya pasos en esta dirección.

"GlaxoSmithKline (GSK) is to sell off several over-the-counter brands, including weight-management drug Alli, as part of efforts to streamline its Consumer Healthcare business.

The company said the products it intends to divest had sales of around £500m for 2010 - around 10 per cent of total turnover for GSK's Consumer Healthcare division for the year."

Ahora "concretan"...

GlaxoSmithKline has sold a block of over-the-counter (OTC) medicines to Belgian company Omega for £391m (€470m) in cash as it continues its revamp of its consumer health operations.

The agreement is expected to conclude in the second quarter of 2012 and includes a number of well-known GSK brands, including Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase, which collectively had sales of around £185m last year.

A condition of the sale is that a manufacturing facility in Herrenburg, Germany, where many of the brands are produced, will be taken over by Omega. The plant employs around 110 people and most are expected to transfer to the new owner.

GSK announced its intention to divest £500m-worth of OTC products last year as part of a wider effort to streamline its business and focus on core brands.

In January, 2012, it completed the sale of another block of OTC products distributed in the US, Canada and Europe with annual sales of around £134m to Prestige Brands Holdings in a deal valued at £426m, after failing to find a global buyer for the entire portfolio.

The latest deal means that GSK has now completed the bulk of its planned divestments, with one tranche of products with annual sales of £60m in markets outside of Europe and North America remaining.

Also outstanding is GSK's OTC weight-loss product Alli (orlistat), which remains on the block but has been restrained by "a temporary third party supply interruption", according to the company.

Alli ya se vende allí…en UK, en España, en Portugal, en Alemania...

-Glaxo informa que su producto antiobesidad (OTC) Alli ya se vende en UK.

-GlaxoSmithKline (GSK) ha lanzado al mercado español 'Allí' (orlistat 60 mg), el primer fármaco sin receta aprobado en Europa para ayudar a las personas con problemas de sobrepeso u obesidad a perder, siguiendo una dieta baja en grasas acompañada de ejercicio.


.../...

Se trata de un fármaco comercializado en botes de 42 u 84 cápsulas, con un precio estimado de 55 euros para el tratamiento de un mes, y se toma tres veces al día, una píldora en cada comida. Está indicado para mayores de 18 años y desaconsejado para embarazadas, trasplantados o pacientes con arritmias o problemas de diabetes.

Mas...

Creatividad: GLAXO / ALLI

Aparecido en ABC, 10 de junio de 2015